Keyword: Levemir

Though Trump convinced Pfizer to delay its planned price increases, Celgene, Roche and Novo have gone through with their own increases in July.

While pricing challenges hit drugmakers in diabetes, Novo Nordisk CEO Lars Fruergaard Jorgensen said portfolio and execution can drive growth.

Novo Nordisk has moved to settle a whistleblower lawsuit alleging the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza and Levemir.

Just over a year ago, Sanofi and Novo Nordisk were touting their new basal insulins as fuel for their diabetes growth engines. But several payers have clamped down on those new meds--Toujeo and Tresiba, respectively--and now, Medicare Part D plans are adding to the pressure.